After receiving FDA breakthrough therapy status for its lead candidate in July, gene therapy company AveXis has released promising new safety and efficacy data. AVXS-101 is being developed to ...

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA), and ...

M.D., Ph.D. AveXis, Inc., a Novartis company, licensed REGENXBIO's NAV adeno-associated virus 9 (AAV9) vector in 2014 and entered into an expanded license for rights to the entire NAV Technology ...

Novartis purchased Zolgensma when they acquired the firm AveXis for a whopping $8.7 billion. What's worse, most health insurance schemes won't insure one-time genetic treatments such as this due to ...

Meanwhile, in Durham, co-founder Jeffs will lead a team focused on development and manufacturing. It will include Britt Petty, AveXis’ former head of global manufacturing and Melissa Rhodes, former ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.